FLUOCINOLONE ACETONIDE OINTMENT, USP, 0.025%
Fluocinolone Acetonide Ointment contains Fluocinolone Acetonide USP (Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α,11β,16α)-. It has an empirical formula of C24H30F2O6 and a molecular weight of 452.49 (CAS Registry Number 67-73-2). Each gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum.
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Media Articles Related to Fluocinolone Ointment (Fluocinolone Topical)
Source: MedicineNet ciclopirox Specialty [2012.03.16]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 3/16/2012 5:47:54 PM
Published Studies Related to Fluocinolone Ointment (Fluocinolone Topical)
A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. [2008.09]
BACKGROUND: Melasma is an acquired, chronic hypermelanosis for which therapy remains a challenge. OBJECTIVES: To compare the efficacy and safety of a triple combination [TC: fluocinolone acetonide 0.01%, hydroquinone (HQ) 4%, tretinoin 0.05%] vs. HQ 4% after 8 weeks of treatment of moderate to severe facial melasma in Asian patients... CONCLUSIONS: Efficacy in Asians and patient satisfaction were superior with the fixed TC than with HQ 4%.
Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. [2007.02]
BACKGROUND: A once-daily fixed combination of hydroquinone, tretinoin, and fluocinolone acetonide (Tri-luma) is a newly available treatment for melasma. OBJECTIVE: To assess cost-effectiveness of triple combination therapy (TCT) applied once daily and hydroquinone alone applied twice daily in the U.S., Argentina, Brazil, Chile, and Colombia from a payer's perspective... CONCLUSION: TCT had a 30% better rate of complete clearing than hydroquinone with a lower cost in the U.S. and an incremental cost in other countries. In every country, cost per primary success was lower for TCT than for hydroquinone. Results were robust to varying assumptions of success rates and quantity used.
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. [2006.06]
PURPOSE: To report the interim 34-week safety and efficacy results of a 3-year study to evaluate an investigational intravitreal fluocinolone acetonide (FA) implant in patients with noninfectious posterior uveitis. DESIGN: Prospective, dose-masked, dose-randomized, historically controlled, multicenter trial in patients with unilateral or bilateral disease. PARTICIPANTS: A total of 278 patients with recurrent noninfectious posterior uveitis were randomized to receive a 0.59-mg (n = 110) or 2.1-mg (n = 168) implant. In patients with bilateral disease, the more severely affected eye received the implant... CONCLUSIONS: The FA implant significantly reduced uveitis recurrences, improved VA, and decreased the need for adjunctive therapy in the studied patient population. The most common side effects included increased intraocular pressure and cataract progression.
Effect of fluocinolone acetonide on human dental pulp cells: cytotoxicity, proliferation, and extracellular matrix formation. [2011.02]
INTRODUCTION: The goal of vital pulp therapy is to maintain pulp vitality and function. Fluocinolone acetonide is a potent topical glucocorticoid used in the treatment of skin disorders and oral lesions that could possibly be used to resolve inflammation and stimulate the healing process of inflamed dental pulp. The purpose of this study was to investigate the effects of fluocinolone acetonide (0.1-50 mumol/L) on cytotoxicity, cell proliferation, and fibronectin and type I collagen synthesis in human dental pulp cells (HDPCs)... CONCLUSIONS: Low concentrations (0.1-10 mumol/L) of fluocinolone acetonide might have the potential to stimulate healing of inflamed dental pulp. Copyright A(c) 2011 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.
Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. [2010.09]
BACKGROUND: Melasma, a disorder of facial hyperpigmentation, presents a treatment obstacle to many physicians. Combination therapy with hydroquinone, tretinoin, and fluocinolone acetonide has proven effective, but it is generally more expensive than other treatments. OBJECTIVE: To assess the cost-effectiveness of daily triple combination therapy (TCT) compared with daily use of each possible pair of agents (dyads) and twice daily use of hydroquinone (HQ) alone from a payer's perspective... CONCLUSION: TCT consistently had the lowest cost per primary success in all the analyses performed. Furthermore, ICERs were low, indicating that TCT's superior efficacy is attained at marginal cost increases. Our results indicate that TCT is the most cost-effective treatment when compared with any of its dyads or with hydroquinone alone.
Clinical Trials Related to Fluocinolone Ointment (Fluocinolone Topical)
Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) [Recruiting]
Purpose: To determine whether a fluocinolone acetonide sustained drug delivery implant is
effective in the treatment of retinal vein occlusion that has caused persistent macular
edema and decreased visual acuity.
Hypothesis: A fluocinolone acetonide sustained drug delivery implant will be a safe and
effective method to treat patients with macular edema and decreased vision from retinal vein
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion [Recruiting]
The purpose of this study is to determine whether a fluocinolone sustained drug delivery
implant is effective in the treatment of central retinal vein occlusion that has caused
persistent macular edema and decreased visual acuity.
Re-Implantation of a Fluocinolone Acetonide Implant for Non-Infectious Uveitis Affecting the Posterior Segment [Recruiting]
The purpose of this study is to collect data on patients with severe uveitis that have
required re-implantation of the sustained-release fluocinolone drug delivery device due to
depletion of study drug in their previous implanted device.
Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema [Active, not recruiting]
This study will evaluate the pharmacokinetics, safety and efficacy of an intravitreal insert
of fluocinolone acetonide for the treatment of diabetic macular edema
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot [Recruiting]
Treatment of exudative age-related macular degeneration has been significantly improved by
the advent of Lucentis™( which provides improved vision rather than simply stabilization) is
common; however, monthly injections may be required to maintain this effect. It is
hypothesized that sustained release fluocinolone acetonide will allow maintenance of the
improved vision with fewer Lucentis injections.